linjc16/ctgov huggingface dataset:
Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil

Study Overview
=================
Brief Summary
-----------------
The investigators would like to study the endothelial function in sickle cell patients without pulmonary hypertension in an in vivo method during a steady state condition before and after sildenafil treatment for 1 month, and to study the effects of this nitric oxide donor by measuring the Flow Mediated Dilatation, by measuring endothelial progenitor stem cells colonies, and by measuring the effect of therapy on markers of inflammation (cell adhesion molecules and cytokines).

Conditions
-----------------
Sickle Cell Anemia

Intervention / Treatment
-----------------
* Drug: Viagra (Sildenafil)
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with sickle cell anemia Exclusion Criteria: patients with sickle cell anemia during acute crisis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: viagra<br>viagra versus placebo will be given to patients with sickle cell anemia | Drug: Viagra (Sildenafil)<br>* Viagra treatment to patients with sickle cell anemia.<br>|
| Placebo Comparator: placebo<br>viagra versus placebo will be given to patients with sickle cell anemia | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function before and after viagra treatment to patients with sickle cell anemia without pulmonary hypertension |  | January 2009 till January 2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endothelial function, endothelial progenitor stem cells
ADL- Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
ADL training of copd patients results in better execution of activities of daily living.

Official Title
-----------------
Activities of Daily Living (ADL)-Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Behavioral: ADL training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD Referred for rehabilitation Age > 18 years Symptoms affecting ADL function 6 minute walk distance (6MWD) < 400 meters Exclusion Criteria: Patients who smokes or has smoked during the last three months. LTOT Patients who has another disability Patients who can't read or speak Norwegian

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1: Standard rehabilitation programme<br> | |
| Experimental: 2. Additional ADL training<br> | Behavioral: ADL training<br>* The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Canadian Occupational Performance Measure(COPM) - Self-perception of occupational performance and satisfaction. |  | Baseline, 4 weeks; 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Pulmonary Rehabilitation, ADL-Training, COPD Rehabilitation
Coronary Interventions Ulm - Coronary Chronic Total Occlusions

Study Overview
=================
Brief Summary
-----------------
The aim of the proposed project is to provide the long-term results after a recanalization attempt of chronically occluded coronary arteries. To investigate recanalization attempt of chronically occluded coronary arteries at the Ulm University Hospital. As shown, it is known that successful recanalization of a chronic occlusion is associated with a lower event rate (reduced mortality and the need for operative myocardial revascularization) compared to unsuccessful recanalization (drug therapy). The standard in the therapy of successfully recanalized chronic occlusions is the use of drug-releasing vascular supports.

Official Title
-----------------
Coronary Interventions Ulm - Coronary Chronic Total Occlusions

Conditions
-----------------
Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion

Intervention / Treatment
-----------------
* Procedure: PCI - percutaneous coronary intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years Coronary intervention in chronic coronary artery occlusion Occlusion > 3 months Indication for PTCA or recanalization according to guidlines such as: Symptoms of the patient Evidence of myocardial ischemia (stress ECG, scintigraphic Methods, magnetic resonance imaging, stress echocardiography) pathological intracoronary flow reserve, prognostic Exclusion Criteria: No chronic occlusion, Contraindication to anti-platelet therapy Acetylsalicylic acid plus clopidogrel for at least 3 months such as e.g. with florid gastrointestinal ulcer disease, History of hemorrhagic stroke or urgent non-postponable surgical intervention. Basic disease with a life expectancy of less than 12 months (here as a rule no indication for PTCA or reopening available)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| successful CTO<br> | Procedure: PCI - percutaneous coronary intervention<br>* percutaneous coronary intervention<br>* Other names: drug eluting stents, Scaffolds, drug eluting ballons;|
| non- successful CTO<br> | Procedure: PCI - percutaneous coronary intervention<br>* percutaneous coronary intervention<br>* Other names: drug eluting stents, Scaffolds, drug eluting ballons;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | major adverse cardiac event | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TLR | target lesion revascularization | 1 year |
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.

Official Title
-----------------
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics. Clinically localized (no evidence on clinical or imaging studies of advanced disease. No hormonal therapy including LHRH agonist or antagonist, anti-androgen, 5-alpha reductase inhibitor, estrogens or exogenous androgens, when applicable. Sufficient amount of tissue remains from biopsy to perform genomic testing. Exclusion Criteria: Patients with known history of hypogonadism will be excluded from the registry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage change from the recorded PRE-Prolaris® test treatment option versus the ACTUAL treatment option of genomic risk assessment testing (Prolaris®). |  | 1 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage change from the recorded PRE-Prolaris® test treatment option versus the POST-Prolaris® test treatment plan (prior to patient consultation). |  | 1 month |
Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot study is to compare the dynamic response of microcirculation in the skin on the bottom of the big toe after applying controlled plantar stress in 25 diabetic subjects with a history of foot ulcer and 25 age-matched healthy controls to better understand the role of local hypoxia in neuropathic foot ulceration in subjects with diabetes. The investigators hypothesize that if they apply a gait simulating load to the plantar foot and measure microvascular function, diabetic individuals will demonstrate an increased delay in reestablishing microvascular flow compared to healthy individuals.

Official Title
-----------------
Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control

Conditions
-----------------
Foot Ulcer, Diabetic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: between ages 40 and 75 history of diabetic neuropathic plantar ulcer (test subjects) no history of diabetes (control subjects) no peripheral sensory neuropathy (control subjects) Exclusion Criteria: amputation or surgery on right Great Toe

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetic Test<br>Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration | |
| Healthy Controls<br>Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Latency time after occlusive loading | The time between removal of occluding pressure and the initiation of the post-occlusive hyperemic response as measured by laser Doppler. | approximately 2.75 minutes after start of collection protocol | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response time to baseline | The time interval between the start of post-occlusive hyperemic response and when the response curve reaches the baseline, or reference, flow level as measured by laser doppler. | 2.75 seconds after start of collection protocol | 
| Response time to Maximum Flow | The time interval between the start of the post-occlusive hyperemic response and the time to reach maximum flow as measured by laser doppler | At least 2.75 seconds after the start of collection protocol. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laser doppler anemometry, dynamic testing of tissue mechanical property, diabetic foot complications, ulcer genesis
Telerehabilitation in Patients With Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
Patients with pulmonary hypertension will be randomized into two groups. One group will receive telerehabilitation sessions including upper and lower extremity strengthening exercises and breathing exercises. The other will me monitored routinely. Patients will be assessed by 6 minute walk test, emphasis-10 questionnaire for quality of life and muscle strength with hand-held dynamometer.

Official Title
-----------------
Investigation of the Effectiveness of a Home Exercise Program Combined With Telerehabilitation in Pulmonary Hypertension Patients

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: Telerehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with pulmonary hypertension Exclusion Criteria: Patients with severe exercise intolerance Patients with musculoskeletal problems that hinder exercise Patients who refuse to join the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise group<br>Patients who receive telerehabilitaton | Other: Telerehabilitation<br>* Patients will attend telerehabilitation sessions<br>|
| No Intervention: Control<br>Patients with routine care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle strength | Muscle strength measured with hand held dynamometer | 3 months |
The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide

Study Overview
=================
Brief Summary
-----------------
Robot assisted laparoscopic radical prostatectomy(Robot-LRP) requires pneumoperitoneum and trendelenburg position which result in oxidative stress and inflammatory response. Propofol is well known to reduce those responses during anesthesia. Therefore, we try to figure out the efficacy of propofol to reduce oxidative stress, inflammatory response and increase the nitric oxide activity during robot-LRP compared to that of desflurane. To investigate the oxidative stress, malondialdehyde will be measured. As inflammatory markers, interleukin-1β, interleukin-6, tumor necrosis factor-α will be measured. Nitric oxide will be measured as well. Secondarily, kidney protection effect of propofol over desflurane will be compared.

Official Title
-----------------
The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: propofol
* Drug: Desflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing robot-assisted laparoscopic radical prostatectomy under general anesthesia Exclusion Criteria: chronic renal failure ( estimated glomerular filtration rate <60 mL/min/1.73m2) allergy to propofol, nuts on diuretics, vitamin C or vitamin E within 5 days before surgery Body mass index > 30 kg/m2 older than 70 years who cannot read the patient consent form

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: desflurane<br>use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS) | Drug: Desflurane<br> <br> |
| Experimental: propofol<br>propofol infusion with target-controlled infusion(TCI) device guided by BIS | Drug: propofol<br> <br> * Other names: fresofol, 2%;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes of serum malondialdehyde, Interleukin-1β, interleukin-6, tumor necrotic factor-α, nitric oxide during operation |  | 100 min after pneumoperitoneum, 10 min after decompression | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kidney function after anesthesia | measure creatinine | 1 day after operation |
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (CAC) test.

Official Title
-----------------
A Phase III Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the CAC Model of Acute Allergic Conjunctivitis in Japanese Subjects

Conditions
-----------------
Allergic Conjunctivitis

Intervention / Treatment
-----------------
* Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
* Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%
* Drug: Olopatadine 0.2% Vehicle
* Drug: Olopatadine 0.1% Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Japanese ethnicity. Seasonal Allergic Conjunctivitis--asymptomatic. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Manifest signs and symptoms of clinically active allergic conjunctivitis in either eye (>1 for redness in any of the 3 vessels beds - conjunctival, episcleral, ciliary - or itching >0) at the start of any visit. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pataday+Pataday Vehicle<br>Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye | Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%<br> <br> * Other names: PATADAY®;Drug: Olopatadine 0.2% Vehicle<br>* Inactive ingredients used as placebo comparator<br>|
| Active Comparator: Patanol+Patanol Vehicle<br>Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye | Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%<br> <br> * Other names: PATANOL®;Drug: Olopatadine 0.1% Vehicle<br>* Inactive ingredients used as placebo comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Ocular Itching Score |  | Day 0 of treatment: 3, 5, and 10 minutes post CAC | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Total Redness Score |  | Day 0 of treatment: 3, 10, 20 minutes post-CAC | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergies, Ocular
Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the typical behavior of children ages 15 months to five years around a microwave oven. The UCH Burn and Complex Wound Center has observed scald burn injuries in young children operating and/or removing hot liquids from microwave ovens. The knowledge we hope to gain is the developmental age that a child is able to open and/or operate a microwave oven safely. This work may influence future microwave oven design to protect young children from microwave-related scald burn injuries. These injuries have resulted in visits to the emergency room, stays in the hospital and debridement and skin grafting procedures in the operating room.

Official Title
-----------------
Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens

Conditions
-----------------
Scald Burn Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a microwave oven in the child's home environment, age appropriate development, intact visual acuity, and English speaking. Exclusion Criteria: developmental delay, non-English speaking.

Ages Eligible for Study
-----------------
Minimum Age: 15 Months
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Typical, Development, Microwave, Children, Behavior